WNT signalling: mechanisms and therapeutic opportunities
Jazyk angličtina Země Anglie, Velká Británie Médium print
Typ dokumentu úvodníky, úvodní články
PubMed
29235106
PubMed Central
PMC5727308
DOI
10.1111/bph.14065
Knihovny.cz E-zdroje
- MeSH
- buněčná membrána účinky léků metabolismus MeSH
- lidé MeSH
- nádory farmakoterapie metabolismus patologie MeSH
- protinádorové látky farmakologie MeSH
- signální dráha Wnt účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- úvodní články MeSH
- úvodníky MeSH
- Názvy látek
- protinádorové látky MeSH
UNLABELLED: This themed section of the British Journal of Pharmacology stems from the EMBO Conference: Wnt Meeting 2016 held from the 14th to 16th September 2016 in Brno, Czech Republic. LINKED ARTICLES: This article is part of a themed section on WNT Signalling: Mechanisms and Therapeutic Opportunities. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.24/issuetoc.
Zobrazit více v PubMed
DeBruine ZJ, Xu HE, Melcher K (2017). Assembly and architecture of the Wnt/β‐catenin signalosome at the membrane. Br J Pharmacol 174: 4564–4574. PubMed PMC
Driehuis E, Clevers H (2017). WNT signalling events near the cell membrane and their pharmacological targeting for the treatment of cancer. Br J Pharmacol 174: 4547–4563. PubMed PMC
Flanagan DJ, Vincan E, Phesse TJ (2017). Winding back Wnt signalling: potential therapeutic targets for treating gastric cancers. Br J Pharmacol 174: 4666–4683. PubMed PMC
Janovská P, Bryja V (2017). Wnt signaling pathways in chronic lymphocytic leukemia and B‐cell lymphomas. Br J Pharmacol 174: 4701–4715. PubMed PMC
Kagey MH, He X (2017). Rationale for targeting the Wnt signalling modulator Dickkopf‐1 for oncology. Br J Pharmacol 174: 4637–4650. PubMed PMC
Kikuchi A, Fumoto K, Kimura H (2017). The Dickkopf1‐cytoskeleton‐associated protein 4 axis creates a novel signalling pathway and may represent a molecular target for cancer therapy. Br J Pharmacol 174: 4651–4665. PubMed PMC
Lyou Y, Habowski AN, Chen GT, Waterman ML (2017). Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy. Br J Pharmacol 174: 4589–4599. PubMed PMC
Mariotti L, Pollock K, Guettler S (2017). Regulation of Wnt/β‐catenin signalling by tankyrase‐dependent poly(ADP‐ribosyl)ation and scaffolding. Br J Pharmacol 174: 4611–4636. PubMed PMC
Ong MS, Cai W, Yuan Y, Leong HC, Tan TZ, Mohammad A et al (2017). ‘Lnc’-ing Wnt in female reproductive cancers: therapeutic potential of long non‐coding RNAs in Wnt signalling. Br J Pharmacol 174: 4684–4700. PubMed PMC
Toledo EM, Gyllborg D, Arenas E (2017). Translation of WNT developmental programs into stem cell replacement strategies for the treatment of Parkinson's disease. Br J Pharmacol 174: 4716–4724. PubMed PMC
van Kappel EC, Maurice MM (2017). Molecular regulation and pharmacological targeting of the β‐catenin destruction complex. Br J Pharmacol 174: 4575–4588. PubMed PMC
Zimmerli D, Hausmann G, Cantù C, Basler K (2017). Pharmacological interventions in the Wnt pathway: inhibition of Wnt secretion versus disrupting the protein‐protein interfaces of nuclear factors. Br J Pharmacol 174: 4600–4610. PubMed PMC
